GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Short Interest

Clearside Biomedical (Clearside Biomedical) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Clearside Biomedical's Short Interest

For the Biotechnology subindustry, Clearside Biomedical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Short Interest distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Short Interest falls into.



Clearside Biomedical (Clearside Biomedical) Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Executives
Charles A. Deignan officer: Chief Financial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay director 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore 10 percent owner 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp director, 10 percent owner C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla officer: Chief Medical Officer C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Daniel H. White director, officer: President and CEO C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond officer: Chief Commercial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701

Clearside Biomedical (Clearside Biomedical) Headlines

From GuruFocus

Clearside Biomedical Announces Leadership Team Update

By Stock market mentor Stock market mentor 02-06-2023